PT - JOURNAL ARTICLE AU - Paul W. Jones AU - Emma L. Low AU - Malcolm McCaughey AU - Abhijit Neil Banik AU - John Farley AU - Jason Victory AU - Jaymin B. Morjaria AU - Dinesh Saralaya AU - Su Mclain-Smith AU - Ruth M. Uden AU - Anzal Qurbain AU - Amr Radwan TI - A prospective observational study of the impact of COPD on daily life following the initiation of indacaterol DP - 2014 Sep 01 TA - European Respiratory Journal PG - P4010 VI - 44 IP - Suppl 58 4099 - http://erj.ersjournals.com/content/44/Suppl_58/P4010.short 4100 - http://erj.ersjournals.com/content/44/Suppl_58/P4010.full SO - Eur Respir J2014 Sep 01; 44 AB - IntroductionGOLD guidelines recommend that the COPD Assessment Test (CAT) (Jones PW, et al. Eur Respir J 2009;34:648-54) is used in routine practice to guide and optimise therapy; however there is little evidence on its use in monitoring treatment. We conducted a 6 month prospective observational study describing the impact of COPD on daily life following initiation of indacaterol, a once-daily, long-acting beta-agonist.MethodsCOPD patients newly prescribed indacaterol for routine COPD management (either as mono-therapy or add-on to long-acting muscarinic antagonists), were recruited from 39 UK GP practices. The CAT was completed at treatment initiation, 6-8 weeks and 6 months, together with physician and patient reported treatment efficacy measures (GETE) and a Daily Living Impact Questionnaire (DLIQ). Treatment changes in addition to indacaterol were also recorded.Results106 participants were recruited (mean age 67), median baseline FEV1 61% predicted (n=103). Median time from diagnosis to indacaterol initiation was 7 months. Results are tabulated (Table 1).ConclusionsIn routine practice, the CAT appears responsive to indacaterol treatment in COPD patients with moderate airflow limitation. In the majority of patients, clinically significant improvements in CAT score were sustained for 6 months. These improvements were reflected in patient and physician reported measures of health status.